Fabry disease (FD; MIM\# 301500) is an X-linked lysosomal storage disorder resulting from a deficiency in α-galactosidase A (GLA) activity. This enzyme defect leads to the systemic lysosomal accumulation of globotriaosylceramide (Gb3) in multiple organs, such as the skin, eyes, kidneys, ears, lungs, heart and brain.^[@bib1]^ Affected males with the classic phenotype of FD present with acroparesthesias, angiokeratomas and hypohidrosis in early childhood or adolescence, progressing to renal insufficiency, cardiomyopathy and cerebrovascular disease in adulthood.^[@bib2]^ Patients with late-onset phenotypes of FD lack the classic symptoms of FD, and their symptoms primarily involve the heart, kidneys, or cerebrovascular systems in adulthood.^[@bib3]^ Clinical manifestations in heterozygous females vary from no symptoms to abnormalities as severe as those in affected males.^[@bib4]^ Enzyme replacement therapy is effective against the progression of FD. Therefore, newborn mass screening is considered important for early treatment before the onset of irreversible organ defects, including renal failure, cardiac disease and early-onset stroke.^[@bib5],[@bib6]^ The plasma or urinary levels of Gb3 in neither hemizygotes nor heterozygotes correlate with the severity of disease manifestations.^[@bib7]^ Plasma Gb3 levels are not useful for the secondary screening of FD, but plasma globotriaosylsphingosine (lyso-Gb3) levels are greatly increased in patients with classic FD. Therefore, lyso-Gb3 levels might be helpful for the secondary screening and severity of FD.^[@bib7; @bib8; @bib9]^

In this pilot study, we performed newborn screening for FD. We measured GLA activity using dried blood spot samples and then analyzed GLA and lyso-Gb3 concentrations.

A pilot study of newborn screening for FD was performed in the hospital of University of the Ryukyus in Okinawa Prefecture, Japan. The study (approval number: H18.12--9) was performed in accordance with the standards of the Ethics Committee in the Ryukyus Graduate School of Medicine (Okinawa, Japan). Dried blood spot samples collected from the heel at 5 days of age were used, and GLA activity was assayed using a fluorescent substrate as previously described.^[@bib6],[@bib10],[@bib11]^ One unit (AgalU) of enzymatic activity was equal to 0.34 pmol of 4-methylumbelliferyl-[d]{.smallcaps}-galactopyranoside cleaved/hour/disc. The results from this assay were repeatedly \<17.0 AgalU in males and \<20.0 AgalU in females. We analyzed all seven exons of *GLA* by direct sequencing from the peripheral blood.^[@bib12]^ Plasma GLA activity was measured as described previously.^[@bib8]^ Plasma lyso-Gb3 concentrations were analyzed by LC--MS/MS using the lyso-Gb3-Gly internal standard.^[@bib13]^ A normal assay result for plasma GLA activity was \>4.0 nmol/hour/ml and that for plasma lyso-Gb3 was \<2.0 ng/ml. The average value and s.d. of the normal control plasma lyso-Gb3 of 1,000 males and females was 0.4±0.3 ng/ml.

A total of 2,443 neonates with informed consent from their guardians were included in the study for 7 years, from May 2007 to September 2014. Thirteen neonates, including two boys and 11 girls, were found to have low GLA activity. The GLA activity in the 11 girls was normal when measured a second time. Because the girls had no family history with clinical information regarding FD, at their request, the analysis of *GLA* was not performed. One boy without a family history of FD had GLA activity of 13.6 AgalU (normal GLA activity: \<17.0) and p.E66Q of *GLA*, previously suggested to be a functional mutation.^[@bib14],[@bib15]^ The other boy showed GLA activity of 6.1 AgalU (normal GLA activity: \<17.0) and p.G144D, which was not previously described. This finding indicated that asparaginic acid was substituted for glycine at the 144th amino acid in *GLA*. His plasma GLA activity was low (0.8 nmol/hour/ml, normal: \>4.0 nmol/hour/ml). Plasma lyso-Gb3 concentrations (normal: \<2.0 ng/ml, mean±s.d.: 0.4±0.3) were 0.9 ng/ml (+1.7 s.d.) at 11 months old and 1.4 ng/ml (+3.3 s.d.) at 21 months old. He was born as the second child to a healthy father and a mother with hypothyroidism. The pregnancy and delivery at 39 weeks of gestation were uneventful. Birth weight was 2,874 g (−0.3 s.d.), length 50.0 cm (+0.47 s.d.) and occipitofrontal circumference 33.0 cm (−0.2 s.d.). At 21 months old, he did not have acroparesthesias, angiokeratomas, or hypohidrosis. Urinary mulberry cells were not observed in a spot of urine. In pedigree analysis, his mother and maternal grandmother also had p.G144D in *GLA* ([Figure 1](#fig1){ref-type="fig"}). Both healthy female relatives showed a normal range of plasma lyso-Gb3 concentrations. The boy's male relatives ([Figure 1](#fig1){ref-type="fig"}, II-2 and III-1) did not participate in the study. The mutation p.G144D was predicted to be disease-causing, as the probable damaging score according to the software PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph/>) was 1.000 and the probability value score according to Mutation Taster (<http://www.mutationtaster.org>) was 0.999. When valine is substituted for glycine at the 144th amino acid in *GLA*, the p.G144V mutation of *GLA* is a disease-causing mutation, previously described as classic FD.^[@bib16]^ Known pathological missense mutations at the same position cause different clinical types of FD (e.g., R112H results in the late-onset type and R112C or R112S in the classic type).^[@bib16; @bib17; @bib18]^ The levels of lyso-Gb3 gradually increase with age in individuals carrying a *GLA* mutation of the late-onset type.^[@bib19]^ The rate of disease onset increases with the elevation of lyso-Gb3 levels in individuals carrying a *GLA* mutation of the late-onset type.^[@bib19]^ We speculate that the p.G144D causes FD as a late-onset type because of the patient's low plasma GLA activity levels, his slightly high plasma lyso-Gb3 levels and the results in his family analysis. Further careful investigation of the boy's male relatives is warranted.
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![Pedigree analysis with results for the *GLA* gene, GLA activity and lyso-Gb3 levels. p.G144D: II-3 and III-2 (heterozygous), IV-3 (hemizygous); GLA activity (normal: \>4.0 nmol/hour per ml): II-3 (3.1), III-2 (4.3) and IV-3 (0.8); lyso-Gb3 (normal: \<2.0 ng/ml): II-3 (0.3), III-2 (0.2) and IV-3 (0.9, 1.4). Neither persons II-2 nor III-1 participated in the study. CA, cerebral aneurysm; CC, carcinoma of the colon; Gb3, globotriaosylceramide; GLA, α-galactosidase A; MI, myocardial infarction; SH, subarachnoid hemorrhage; Y, years of age.](hgv20172-f1){#fig1}
